Unlocking oncoembryonic programs for clinical advances in cancer therapy

Tosca Dalessi; Hassan Fazilaty

doi:10.1002/ctm2.70409

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (7) : e70409 DOI: 10.1002/ctm2.70409

COMMENTARY

Unlocking oncoembryonic programs for clinical advances in cancer therapy

Author information +

History +

PDF

Keywords

cancer plasticity / developmental reprogramming / oncoembryonic programs / precision oncology / therapy resistance

Cite this article

Download citation ▾

Tosca Dalessi, Hassan Fazilaty. Unlocking oncoembryonic programs for clinical advances in cancer therapy. Clinical and Translational Medicine, 2025, 15(7): e70409 DOI:10.1002/ctm2.70409

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Virchow RLK, Hirshcwald A. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Verlag von August Hirschwald; 1859.

[2]	Krebs ET. Cancer and the embryonal hypothesis. Calif Med. 1947; 66: 270-271.

[3]	Fazilaty H, Basler K. Reactivation of embryonic genetic programs in tissue regeneration and disease. Nat Genet. 2023; 55: 1792-1806.

[4]	Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315: 1650-1659.

[5]	Pobbati AV, Hong W. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020; 10: 3622-3635.

[6]	Picozzi V, Alseidi A, Winter J, et al. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 2020; 5: e000668.

[7]	Fazilaty H. Restoration of embryonic gene expression patterns in tissue regeneration and disease. Nat Rev Mol Cell Biol. 2023; 24(6): 375-376.

[8]	Nguyen C, Yi C. YAP/TAZ signaling and resistance to cancer therapy. Trends Cancer. 2019; 5: 283-296.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.